Insider

Penumbra Inc

PEN Health Care · 1 analysis · 1 expectation tracked

Penumbra reported $410M in revenue (+15.6% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 1 open management expectation for this company.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Penumbra reports higher revenue, lower net income

Penumbra, Inc. reported its third-quarter results on October 29, 2026, recording a 7.8% decline in net income and an 8.5% drop in earnings per share (EPS) compared to the same period last year. Despite overall revenue growth, these figures indicate a shift in business profitability for the quarter.

· Penumbra Inc

Company history

October 2026

Penumbra Inc: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-29: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 410,145,000 USD (410 million); same period a year earlier (2025-07-01 to 2025-09-30): 354,685,000 USD (355 million); change +15.6% Source
  • 2026-10-29: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-30: 1,174,949,000 USD (1.2 billion; 1,175 million); same period a year earlier (2025-01-01 to 2025-09-30): 1,018,280,000 USD (1 billion; 1,018 million); change +15.4% Source
  • 2026-10-29: Gross profit (us-gaap:GrossProfit), quarter 2026-07-01 to 2026-09-30: 280,303,000 USD (280 million); same period a year earlier (2025-07-01 to 2025-09-30): 240,416,000 USD (240 million); change +16.6% Source
  • 2026-10-29: Gross profit (us-gaap:GrossProfit), year to date 2026-01-01 to 2026-09-30: 798,658,000 USD (799 million); same period a year earlier (2025-01-01 to 2025-09-30): 680,309,000 USD (680 million); change +17.4% Source
  • 2026-10-29: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 50,739,000 USD (51 million); same period a year earlier (2025-07-01 to 2025-09-30): 48,838,000 USD (49 million); change +3.9% Source
  • 2026-10-29: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 130,012,000 USD (130 million); same period a year earlier (2025-01-01 to 2025-09-30): 130,016,000 USD (130 million); change 0% Source
  • 2026-10-29: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 42,279,000 USD (42 million); same period a year earlier (2025-07-01 to 2025-09-30): 45,851,000 USD (46 million); change -7.8% Source
  • 2026-10-29: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 109,674,000 USD (110 million); same period a year earlier (2025-01-01 to 2025-09-30): 130,344,000 USD (130 million); change -15.9% Source
  • 2026-10-29: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 174,563,000 USD (175 million); same period a year earlier (2025-01-01 to 2025-09-30): 152,179,000 USD (152 million); change +14.7% Source
  • 2026-10-29: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-30: 42,320,000 USD (42 million); same period a year earlier (2025-01-01 to 2025-09-30): 45,295,000 USD (45 million); change -6.6% Source
  • 2026-10-29: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 254,282,000 USD (254 million); previous balance (2025-12-31): 186,897,000 USD (187 million); change +36.1% Source
  • 2026-10-29: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 1,583,509,000 USD (1.6 billion; 1,584 million); previous balance (2025-12-31): 1,427,603,000 USD (1.4 billion; 1,428 million); change +10.9% Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 29, 2026. SEC

LatestEarlierChange
Revenue quarter$410M$355M+15.6%
Operating income quarter$50.7M$48.8M+3.9%
Net income quarter$42.3M$45.9M-7.8%
Diluted EPS quarter$1.07$1.17-8.5%
Operating cash flow year to date$175M$152M+14.7%
Cash and cash equivalents balance$254M$187M+36.1%

Next results expected around January 28, 2027 (estimate: the quarter ending about December 30, 2026 plus the 29 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Penumbra Inc PEN$410M+15.6%12.4%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • The merger with Boston Scientific Corporation is expected to close in early 2027.

    Said October 29, 2026 · Period named: early 2027 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock4,300,206$1,368,927,577+0.1%Q3 2026
State Street1,236,104$393,501,347-0.6%Q3 2026
Millennium Management1,039,025$330,763,219+48.3%Q3 2026
Geode Capital Management785,573$250,140,707-1.4%Q3 2026
Norges Bank (Norway's sovereign fund)752,242$237,520,412—Q2 2026
Two Sigma Investments328,937$104,713,805-23.2%Q3 2026
Citadel Advisors252,696$80,443,245-43.7%Q3 2026
Soros Fund Management203,434$66,801,623—Q1 2026
D. E. Shaw & Co.146,773$46,723,716-25.6%Q3 2026
Fidelity (FMR)85,566$27,239,184-59.4%Q3 2026
Renaissance Technologies46,660$14,853,744-41.3%Q3 2026
Wellington Management20,388$6,437,511-6.5%Q2 2026
Bridgewater Associates1,474$469,233-6.7%Q3 2026
T. Rowe Price43,779$13,938-1.9%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.